PET Imaging

Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enables visualization of metabolic processes in the body. The basics of PET imaging is that the technique detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (also called radiopharmaceuticals, radionuclides or radiotracer). The tracer is injected into a vein on a biologically active molecule, usually a sugar that is used for cellular energy. PET systems have sensitive detector panels to capture gamma ray emissions from inside the body and use software to plot to triangulate the source of the emissions, creating 3-D computed tomography images of the tracer concentrations within the body.

FDA-approved in May 2023, POSLUMA is commercially available through 36 radiopharmacies across the United States
News | Prostate Cancer
Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

July 28, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 28, 2023
arrow
Scientists have found a new use for copper in magnetic resonance imaging (MRI) contrast agent design, that could help to create better images which help doctors diagnose patients’ conditions more easily and safely.
News | Magnetic Resonance Imaging (MRI)
Copper Could Help Create Clearer MRI Images and Improved Diagnosis

July 27, 2023 — Scientists have found a new use for copper in magnetic resonance imaging (MRI) contrast agent design ...

Time July 27, 2023
arrow
Researchers at Monash University have designed a new co-training AI algorithm for medical imaging that can effectively mimic the process of seeking a second opinion.
News | PET Imaging
PSMA PET Imaging Improves Accuracy of Predicting Prostate Cancer Recurrence

July 26, 2023 — A molecular imaging tool developed by researchers at the University of California’s two nationally ...

Time July 26, 2023
arrow
A collaboration to advance development of a fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers. 
News | Radiopharmaceuticals and Tracers
Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

July 25, 2023 — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative ...

Time July 25, 2023
arrow
For teleradiology groups, ensuring they have the radiologist capacity and technology in place will be essential to capitalize on the opportunity for robust market growth
Feature | Teleradiology | By Arun Gill
Outpatient Imaging And Teleradiology Changing the Market Dynamic in the US

The healthcare market is witnessing a dynamic shift in how and where patients want to receive care, with the flexibility ...

Time July 12, 2023
arrow
A collaboration to advance development of a fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers
News | Radiopharmaceuticals and Tracers
First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

July 11, 2023 — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative ...

Time July 11, 2023
arrow
City of Hope researchers establish foundation to expand SCINTIX therapy using a prostate cancer-specific PET radiotracer
News | Prostate Cancer
RefleXion Highlights Clinical Study Results for Future Prostate Cancer Treatment

July 3, 2023 — RefleXion Medical, Inc., a therapeutic oncology company, today announced that results of a prospective ...

Time July 03, 2023
arrow
A newly discovered radionuclide-based agent (CB-2PA-NT) has been shown to have high tumor uptake, sustained tumor retention, and high contrast in preclinical models, making it a prime candidate for a novel theranostics approach
News | SNMMI
Novel Theranostic Agent Targets Multiple Cancer Types

June 28, 2023 — A newly discovered radionuclide-based agent (CB-2PA-NT) has been shown to have high tumor uptake ...

Time June 28, 2023
arrow
A novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity compared to 99Tc-SPECT myocardial perfusion imaging (MPI)
News | SNMMI
Novel Radiotracer Demonstrates High Diagnostic Efficacy for Obese Patients with Coronary Artery Disease

June 28, 2023 — A novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese ...

Time June 28, 2023
arrow
Nizar A. Mullani, one of the pioneers of the first positron emission tomography (PET) prototype, has been named as this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award.
News | SNMMI
Nizar A. Mullani Receives SNMMI 2023 Georg Charles de Hevesy Nuclear Pioneer Award

June 26, 2023 — Nizar A. Mullani, one of the pioneers of the first positron emission tomography (PET) prototype, has ...

Time June 26, 2023
arrow
News | SNMMI
Study on Value of 68Ga-FAPI PET/CT Imaging for Evaluation of Disease Activity in Rheumatoid Arthritis presented during SNMMI 2023

June 26, 2023 — PET imaging with 68Ga-FAPI offers a feasible, reliable, and reproducible method for evaluating disease ...

Time June 26, 2023
arrow
A new PET radiotracer that visualizes the enzyme primarily responsible for metabolic cholesterol degradation in the brain has been successfully validated
News | SNMMI
Translational PET Tracer Visualizes Brain Cholesterol Metabolism

June 25, 2023 — A new PET radiotracer that visualizes the enzyme primarily responsible for metabolic cholesterol ...

Time June 25, 2023
arrow
News | SNMMI
Ultra-High Resolution Brain PET Scanner Visualizes and Quantifies Brainstem Nuclei for the First Time

June 24, 2023 — A new ultra-high resolution (UHR) brain PET scanner may have the ability to characterize previously ...

Time June 24, 2023
arrow
 A newly developed technology called “augmented whole-body scanning via magnifying PET” (AWSM-PET) has been shown to enhance the image resolution and system sensitivity of clinical whole-body PET/CT imaging.
News | SNMMI
New Whole-Body PET Technology Offers Cost-Effective Solution to Improve Image Resolution and Sensitivity

June 24, 2023 — A newly developed technology called “augmented whole-body scanning via magnifying PET” (AWSM-PET) has ...

Time June 24, 2023
arrow
POSLUMA is now commercially available in multiple U.S. radiopharmacies, with nationwide availability by end of June 2023
News | Prostate Cancer
Blue Earth Diagnostics and PETNET Solutions Inc, A Siemens Healthineers Company, Announce U.S. Commercial Availability of POSLUMA (Flotufolastat F 18) Injection for PET Imaging of Prostate Cancer

June 21, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time June 21, 2023
arrow
The first patient has been scanned in a Phase I clinical trial for an investigational fluorine-18 (18F) CD8-targeted imaging radiopharmaceutical
News | Radiopharmaceuticals and Tracers
First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies

June 15, 2023 — With immunotherapy emerging as one of the most important treatment options in oncology, GE HealthCare ...

Time June 15, 2023
arrow
POSLUMA (flotufolastat F 18) PET/CT image showing uptake in the prostate gland, consistent with primary prostate cancer Photo courtesy of Blue Earth Diagnostics
News | Radiopharmaceuticals and Tracers
U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

May 30, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 30, 2023
arrow
In March 2023, Appropriate Use Criteria (AUC) for ER-targeted PET imaging was also published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI)
News | Breast Imaging
GE HealthCare Announces FES PET Imaging Recommendation in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)

May 25, 2023 — GE HealthCare, a leader in breast cancer care technology and diagnostics, has today announced that NCCN ...

Time May 25, 2023
arrow
UCLA investigators present the latest cancer research at the American Society of Clinical Oncology annual meeting June 2 to June 6 in Chicago
News | Radiation Oncology
Targeted Therapy for Early Breast Cancer, Progress Treating Recurrent Glioma, PSMA PET Scan Advances Research Presented

May 22, 2023 — Physicians and scientists from the UCLA Jonsson Comprehensive Cancer Center will discuss the latest ...

Time May 22, 2023
arrow
Parametric maps of amyloid deposition in healthy control participants (A and B) and blast-exposed military instructors (C and D) at baseline (A and C) and follow-up (B and D). The blue-to-red scale indicates the frequency of statistically abnormal amyloid uptake in a particular brain voxel. Whereas no abnormal amyloid uptake was identified at baseline or follow-up in healthy control participants (A, B), amyloid deposition occurred most frequently in blast-exposed participants in the superior parietal lobule
News | PET Imaging
Recurrent Brain Trauma May Increase Alzheimer’s Risk

May 22, 2023 — New research finds that the brains of otherwise healthy military personnel who are exposed to explosions ...

Time May 22, 2023
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now